X4 Pharmaceuticals(US:XFOR) Globenewswire·2026-02-03 12:00Core Insights - X4 Pharmaceuticals will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York, highlighting its commitment to addressing rare hematology diseases [1] - The management team will engage in a fireside chat on February 12th at 12:30 p.m. ET and will be available for one-on-one meetings with investors, indicating proactive investor relations [1] - A webcast of the fireside chat will be accessible on the company's website, with a replay available for 30 days, enhancing transparency and investor engagement [2] Company Overview - X4 Pharmaceuticals focuses on developing and commercializing innovative therapies for patients with rare hematology diseases and significant unmet needs, showcasing its dedication to improving patient outcomes [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, which is currently marketed in the U.S. as XOLREMDI® for its first indication, demonstrating its progress in therapeutic development [3] - X4 is conducting a global, pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with certain chronic neutropenic disorders, indicating ongoing research and development efforts [3]